Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity?

Currents International Trade Law Journal, Summer 2013

21 Pages Posted: 4 May 2013 Last revised: 2 May 2019

See all articles by Michael Palmedo

Michael Palmedo

American University - Program on Information Justice and Intellectual Property; American University

Date Written: 2013

Abstract

Countries may choose various methods of data protection in order to comply with the TRIPS Agreement. Policymakers should consider the effects of data exclusivity on prices and investment relative to other types of data protection. The data presented here suggest there is no relationship between whether or not a country has data exclusivity, and the amount of investment in the country by the pharmaceutical industry. On the other hand, empirical evidence in previous papers has shown that data exclusivity does drive prices higher.

Keywords: intellectual property, IP, pharmaceutical

JEL Classification: O31, O34, O38

Suggested Citation

Palmedo, Michael, Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity? (2013). Currents International Trade Law Journal, Summer 2013, Available at SSRN: https://ssrn.com/abstract=2259797

Michael Palmedo (Contact Author)

American University - Program on Information Justice and Intellectual Property ( email )

4801 Massachusetts Avenue N.W.
Washington, DC 20016
United States

American University ( email )

4400 Massachusetts Ave, NW
Washington, DC 20016
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
345
Abstract Views
1,687
rank
107,511
PlumX Metrics